Home Health How COVID-19 treatment is related to malaria drugs?
HealthNews

How COVID-19 treatment is related to malaria drugs?

Share
COVID-19
Share

Russia’s Federal Biomedical Agency on Saturday said it has developed a drug for the treatment of COVID-19.

The agency said its drug was based on mefloquine, which is used to prevent or treat malaria.

The drug will allegedly provide effective treatment for COVID-19 patients with varying severity.

According to the agency’s statement, the drug prevents virus replication in cells and as a result, stops the inflammatory process caused by the virus.

Veronika Skvortsova, the agency’s head, said Mefloquine has to be combined with antibiotics for the maximum effect, allowing an increase in the concentration of antiviral agents in blood plasma and lungs.

This will ensure effective treatment of patients with various degrees of coronavirus infection, Skvortsova said.

The agency said it was developing an effective and safe scheme for the prevention of coronavirus on the basis of mefloquine.

The treatment was developed taking Chinese and French experience into account, it added.

COVID-19 treatment, for now, focuses on relieving symptoms such as breathing assistance.

Companies around the world are racing to develop vaccines. A few have launched early safety testing in humans, but experts say it could take a year or more to develop and test a vaccine.

Although Russia claims to have found the cure based on malaria treatment drug, Confiance News gathered that Donald Trump had earlier affirmed to the use of chloroquine, also a drug known for the treatment of malaria, owing to its effectiveness in treating COVID-19 patients.

“HYDROXYCHLOROQUINE & AZITHROMYCIN, taken together, have a real chance to be one of the biggest game changers in the history of medicine. The FDA has moved mountains – Thank You! Hopefully they will BOTH (H works better with A, International Journal of Antimicrobial Agents)…..,” he tweeted.

However, leading infectious disease experts have urged the public to remain cautious until larger clinical trials validate smaller studies.

 

(DAILY SABAH)

Please follow and like us:
Share

Leave a comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Member

Don't Miss

NCC Addresses Quality of Service Issues in Abuja‎

‎By Chioma Obinagwam ‎‎The Nigerian Communications Commission (NCC) is aware of the recent Quality of Service (QoS) challenges affecting telecommunications subscribers in Abuja,...

‎Why spiritual power triumphs over others

By Chioma Obinagwam‎‎In a timely and urgent New Year message delivered at the Redeemed Christian Church of God (RCCG) Solidrock Parish in Lagos...

Related Articles

NCC Addresses Quality of Service Issues in Abuja‎

‎By Chioma Obinagwam ‎‎The Nigerian Communications Commission (NCC) is aware of the...

‎Why spiritual power triumphs over others

By Chioma Obinagwam‎‎In a timely and urgent New Year message delivered at...

‎First Bank hits ₦500bn CBN recapitalisation target: Otedola’s strategic influence‎

By Chioma Obinagwam‎‎In a major boost to Nigeria’s banking sector, First Bank...

‎How Nigeria’s new tax law could redefine risk in the banking sector

‎‎By Blaise Udunze‎‎On Friday, January 1, 2026, Nigeria launched its nationwide tax...